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Abstract
The fascinating history of local anesthetics (LAs) began in South America with 
the herbal and traditional use of cocaine leaves by the indigenous peoples of Peru 
and Bolivia, the sacred plant of the Incas Erythroxylum coca. The use for anesthetic 
purposes dates back to 1884. Since then, the evolution of LAs has been closely 
related to research motivated by its efficacy and safety versus toxicity. According to 
their chemical structure, these drugs are classified into two main groups: esters and 
amino amides; however, there are three LAs with different characteristics: articaine, 
sameridine, and centbucridine. The pharmacological and toxic mode of action is 
primarily in the voltage-dependent sodium channels located in the cell membrane, 
which clinically produces analgesia, anesthesia, seizures, arrhythmias, and cardiac 
arrest. The quality of anesthesia and analgesia depends on the type of LA, dose, 
and application technique, while the deleterious effects are secondary to its plasma 
concentration. Nonanesthetic properties of LAs such as their antimicrobial, 
antineoplastic, antiarrhythmics, antitussive, and antiasthmatics effects have been 
described and are briefly reviewed.
Keywords: local anesthetics, pharmacology, toxicity
1. Introduction
Local anesthetics (LAs) are drugs commonly used in medicine and especially in 
anesthesiology, which when administered in the vicinity of peripheral neural tissue 
produce changes in the conformation of voltage-dependent sodium channels that 
depolarize the neural tissue and produce analgesia, anesthesia, and sympathetic and 
motor block in the dermatomes of the affected nerves without altering consciousness. 
This inhibitory phenomenon is reversible and transitory and is known as regional 
anesthesia and is classified into local, peripheral nerves, nervous plexuses, peridural, 
subarachnoid, and intravenous anesthesia.
LAs are safe and effective drugs, although when wrongly managed, they can reach 
high plasma concentrations and produce systemic toxicity (LAST) that manifests 
primarily in the central nervous system (CNS) and cardiovascular system (CVS), 
causing side effects that can occasionally lead to death. Local neuro toxicity has also 
been described when injected in the vicinity of the peripheral nervous system or at 
subarachnoid or epidural space. Myotoxic effects have also been described.
The main clinical use of LAs is to achieve pain insensitivity, although they 
have other pharmacological uses such as antiarrhythmic, anti-asthmatic, anti-
inflammatory, antithrombotic, bacteriostatic, and bactericidal effects that have 
been demonstrated, as well as antitumoral agent enhancer activity [1–3]. LAs are 
grouped into two categories: those of the ester type and those of the amino-amide 
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group. They are the only drugs used in regional anesthesia, although it has been 
described that other drugs with different molecular structure such as amitriptyline, 
meperidine, eugenols, beta-adrenergic antagonists, alpha2 agonists, spasmolytics, 
anticonvulsants, and antihistamines have local anesthetic effects [4–6]. There are 
three LAs that due to their chemical structure differ from the classic LAs: articaine, 
sameridine, and centbucridine. Articaine is classified into the amide group, it is fat 
soluble and short acting and has intermediate potency, with rapid metabolism due 
to an ester group in its structure. Sameridine, on the other hand, has mixed effects 
as an opioid agonist and LA properties under investigation for intrathecal use [7, 8]. 
Centbucridine is a nonester, nonamide drug still under clinical investigation [9].
In this introductory chapter, the most important properties of LAs are detailed, 
emphasizing their pharmacological classification, pharmacokinetic profile, action 
mechanisms, side effects, and some relevant clinical aspects, as well as their 
nonanesthetic uses.
2. Brief history of the discovery and evolution of LAs
In the Andean Mountains, centuries ago, the Incas began using cocaine leaves 
which they chewed or ingested in the form of potions that provided them with 
plenty of energy to carry out their religious rituals. In addition, as a powerful 
stimulant, the coca leaf was chewed to mitigate the effects derived from altitude, 
hunger or fatigue and as a medicine for gastrointestinal discomfort, colds, or 
bruises. This sacred plant of the Incas, Erythroxylum coca, caught the attention of 
Europeans who took it to the old continent at the end of the 16th century. It was 
until 1859 when Paulo Mantegazza, an Italian physiologist, wrote Sulle virtu igien-
iche e Medicinale della Coca (On the hygienic and medicinal properties of coca and 
on nervine nourishment in general) where he pointed out its healing properties. The 
German chemist Albert Niemann isolated the active substance from these leaves 
and called it cocaine, noting its power to anesthetize the tongue. In 1884, Sigmund 
Freud wrote his famous monograph entitled Ueber coca. Like some of his contempo-
raries, Freud acknowledged that cocaine had local anesthetic effects when applied 
to the mucous membranes, but it was Karl Köller who used it for the first time for 
anesthetic purposes when applied in various mucous membranes and in the con-
junctiva for surgical purposes. It is Köller to whom it is attributed the beginning of 
local anesthesia [10–12].
The knowledge of the toxic and additive effects of cocaine became public 
quickly; it went from being the LA in vogue to a potent CNS stimulant that until 
today is a social stigma. This fired the investigation toward new LAs, and safer 
drugs were found. Benzocaine was synthesized in 1890, and in 1904, Alfred 
Einhorn introduced procaine by degrading cocaine, which was later marketed as 
novocaine® and was the most widely used LA in the world. Tetracaine was syn-
thesized in 1928 and introduced into clinical anesthesia in 1932. In 1943 Löfgren 
discovered lidocaine that was introduced for clinical use in 1947 and is currently 
the most used LA. Mepivacaine appeared in 1956, and in 1963, the clinical use of 
bupivacaine was introduced, while etidocaine began to be used in 1972. Other LAs 
appeared during the following years but were withdrawn from the market due 
to their toxic effects. In 1970, Albrigth [13] mentioned some deaths attributed to 
bupivacaine and etidocaine. His editorial was enough to start basic and clinical 
research in search of new drugs with a better safety profile. The result was the 
introduction of ropivacaine in 1997 and levobupivacaine in 1999, both levoisomeric 
drugs. It is noteworthy that these two LAs had been discovered in 1957 and 1972, 
respectively (Table 1).
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The levoisomeric LAs did not replace other LAs but are complementary to the 
therapeutic armamentarium in regional anesthesia. Both ropivacaine and levobu-
pivacaine have been conquering a special place in regional anesthesia techniques, 
but their toxicity is still superior to procaine, chloroprocaine, and lidocaine. While 
these LAs are not comparable in potency and duration, they still have a place in 
anesthesiology, with the exception of intrathecal lidocaine. The history of these 
drugs will continue to be written as new results on therapeutic effectiveness and 
toxicity are obtained.
3. Basics data
It is necessary to know some elementary aspects of the structure and function of 
the cell membrane, as well as to understand the role of voltage-dependent sodium 
channels, which are protein structures that are located in the cell membrane and 
play a paramount role in cellular electrical activity and impulse transmission.
3.1 Cellular membrane
The cell membrane is a barrier of lipids and proteins, which forms the outer 
surface of eukaryotic cells. The lipid part of the membrane is formed by a bilayer 
with a thickness of 60–100 Å, which gives it structure and constitutes a barrier 
that prevents the passage of water-soluble substances. It has three important 
types of lipids: phospholipids, glycolipids and cholesterol. The membrane pro-
teins are suspended individually or in groups within the lipid structure and shape 
the various channels. The selectivity of transmembrane protein channels allows 
the cell to control the entry and exit of substances, as well as transport between 
cell compartments. Membrane proteins not only facilitate selective transport, but 
in addition, they are able to carry out active transport against the concentration 
gradient with special pumps, such as the sodium-potassium pump. Other func-
tions of the membrane, such as the recognition and binding of certain substances 
on the cell surface, are also determined by the protein part of the membrane. 
These proteins are called cell receptors.
Local anesthetics Year of synthesis Introduction in clinic
Cocaine 1860 1884
Procaine 1904 1905
Dibucaine 1925 1930
Tetracaine 1928 1932
Lidocaine 1943 1947
Chloroprocaine 1950 1952
Mepivacaine 1956 1957
Prilocaine 1959 1960
Bupivacaine 1957 1963
Etidocaine 1971 1972
Ropivacaine 1957 1997
Levobupivacaine 1972 1999
Table 1. 
Chronological appearance of local anesthetics.
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Cellular receptors are connected to internal systems that only act when certain 
substances bind to the membrane surface. Many of the cell controls act through 
this mechanism. Some metabolic pathways do not take action unless the “signal” 
molecule—for example—a hormone, has reached the cell surface. Glycoproteins 
are located in the membrane that identify other cells as members of an individual or 
as strangers. The interactions between the cells that make up a tissue are based on 
membrane proteins. In this manner, the structure of the membranes depends on the 
lipids, while the functions depend on the proteins.
3.2 Physiology of nerve transmission
The resting cell membrane maintains a voltage difference of 40–90 mV between 
the inner and outer layers, the inside being negative and the outside positive. This 
is the so-called resting potential, which is maintained by an active mechanism of 
the Na/K pump. The polarized membrane does not allow the passage of sodium ions 
(Na+) through the voltage-dependent sodium channels that are in resting state. When 
an electrical stimulus arrives, the membrane depolarization begins by activating 
the sodium channels that open to give way to the Na+, which enter the intracellular 
medium, transforming the negativity of the transmembrane potential. This initiates 
a cycle of changes of sodium channels in four functional stages: resting, activated, 
inactivated, and deactivated. In the resting state, the outer gate of the sodium 
channel is closed, and the internal gate or closing gate is open. When a stimulus 
reaches the membrane, the sodium channel is activated by opening the external 
gate and letting Na+ pass. When the membrane potential rises to +20 mV, the 
closure of the internal gate is triggered, and it enters an inactive state. The channel 
is deactivated when the membrane potential reaches −60 mV. When the passage of 
Na+ ceases through the pore of the sodium channel, the potassium channel increases 
its permeability, allowing this ion to pass inside the cell due to differences in con-
centration (concentration gradient). Then the initial phase is restored; the Na-K 
pump mobilizes Na+ outside and K+ inside the cell. Sodium channels pass from the 
inactive-deactivated state to the initial resting state. All these movements of Na+ and 
K+ are manifested in changes in the transmembrane electrical potential, generating 
the action potential that is propagated along the nerve fiber (Figure 1) [14]. Because 
there is a potential difference across the cell membrane, the membrane is said to be 
polarized. If the membrane potential becomes more positive than it is at the resting 
potential, the membrane is said to be depolarized. This whole process lasts 1 mil-
lisecond; 30% is consumed by the depolarization phase. According to the electrical 
instant, the sodium channels dependent on voltage exist in four stages; resting 
(−90 mV), activated (−60 mV), inactivated (+20 mV) and deactivated (−60 mV).
3.3 Voltage-dependent sodium channels
Hodgkin and Huxley proposed that cell membranes contained channels that 
facilitated ionic passage through them, which was confirmed when ionic currents 
that selectively flow through these transmembrane pores were directly measured. 
In 1972, Singer and Nicolson [15–17] proposed the ¨Fluid Mosaic Model¨ in the 
structure of the cell membranes were they described the cell membrane as a two-
dimensional liquid that restricts the lateral diffusion of membrane components and 
includes the integral proteins inserted in the lipid bilayer, some of which completely 
cross it and others cross it partially. Of these membrane proteins, three primary 
groups stand out: the channels, pumps, and receptors that constitute the transport 
system through cell membranes and regulate the movements of small molecules and 
ions that cannot pass through the lipid bilayer.
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Sodium channels are protein structures that are integrated into the lipid bilayer 
of the cell membrane and are responsible for orchestrating the electrical signals 
that are transmitted by certain tissues, such as nerves and the heart’s electrical 
conduction system. They are tubular-shaped components that resemble pores filled 
with water and are distributed through the whole cell membrane, primarily at the 
beginning of axons and in Ranvier nodes. This ion channels are divided into three 
types; those regulated by voltage, those regulated by extracellular ligand and those 
regulated by intracellular ligands, although other authors classify them into only 
two groups; those regulated by voltage and those operated by receptors [18–20]. 
The family of voltage-regulated sodium channels is composed of nine members that 
have been described in mammals and a tenth component related to a protein. All of 
them are members of a super family of ion channels that also includes potassium 
and calcium channels. Its nomenclature is complex and the chemical symbol of 
sodium Na+ is used first, followed by V indicating voltage regulated (Na+ V). The 
next number indicates the subfamily gene (Na+ V1), and the next number identifies 
the specific isoform of the channel, for example Na+ V1.1. This last number was 
assigned in the chronological order in which the genes were discovered. There are 
variants that come together or splice in each family member, which are told apart 
from each other by a lowercase letter, for example Na+ V1.1. a. [18, 19].
The sodium channels are formed by an alpha subunit, a simple polypeptide 
with a relative molecular mass of ~260,000 and are responsible for the selectivity 
and gate voltage. Some sodium channels have beta 1 and 2 subunits. These sodium 
ionophores are made up of four homologous domains; each of these four domains 
contains six transmembrane segments known as alpha-helices. This causes each 
sodium channel to cross the cell membrane 24 times. The center of this structure is 
the channel pore through which the Na+ passes into the interior of the cell and also 
the LAs in their hydrophilic form on their way to be fixed in the internal pore of the 
Figure 1. 
Representation of the four structural phases of sodium channels and their relationship with the action potential. 
Modified from Columb MO, MacLennan K. Local anesthetics agents. Anaesth Intensive Care Med 2007;  
8: 159–162 [14].
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sodium channel, where the voltage sensor is located. This voltage sensor is located in 
the fourth segment of each domain, where the LAs are fixed in the sixth segment of 
Domains 3 and 4. The voltage sensor has a very high positive charge, and these four 
domains are connected to each other by segments or hydrophilic bridges formed by 
amino acids that are located on the extracellular side of the membrane. The bridge 
that joins segments 5 and 6 of each domain is known as a pore handle and covers 
the pore of the channel to allow only the passage of Na+. This channel structure is 
responsible for selectivity and is vulnerable to certain toxins that can inactivate the 
sodium channel, although another description mentions that the selectivity filter is 
given by a narrowing of the ionic pore located below its gate [19].
The gate of the ionic pore is the initial portion of the sodium channel on the 
outer side of the cell membrane, is made up of protein “walls” and has an aqueous 
cavity similar to an irregular cylinder, where the external vestibule is located, which 
contains the selectivity filter and the voltage sensor. The closure gate is located 
in the most distal portion of the sodium channel, on the intracellular side of the 
cell membrane. The sodium channel inlet measures about 1.2 nm and narrows to 
about 0.3 to 0.5 nm at the site where the selectivity filter is located, which consists 
of aspartic acid, glycine, lysine, and alanine. The exact mechanism of how these 
channels discriminate between different cations is not known [19].
Figure 2 shows a representation of a voltage-dependent sodium channel, 
which is in the lipid bilayer of the cell membrane. Its four domains (D1, D2, D3, 
and D4) are each made up of six segments (alpha helices) that cross the entire cell 
membrane, emphasizing segment 4, colored in black and corresponding to the 
voltage sensor, which has a positive charge. On the extracellular face of the cell 
membrane there are two types of structures that connect the six segments, the one 
marked with T between segments 5 and 6 of each domain represent the site where 
some toxins act. The FS selectivity filter in the initial portion of the ionic pore 
is shown. The site where LAs act is marked with an X. This site has been highly 
Figure 2. 
Diagram of the voltage-dependent sodium channel with its 4 domains. Each domain has 6 helices that cross 
the cell membrane. The black stars located at the junctions of the helices 5 and 6 of each domain (pore handle) 
are the sites where cellular toxins (TTX) act. The sodium channel inactivation gate (IC) is located on the 
intracellular face between domain 3 and 4. The effector site of local anesthetics is located on helix 6 (or segment 
6) of domains 3 and 4, although some schemes also draw it in domain 1.
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controversial and is located in the final portion of the ionic pore near the intracel-
lular surface of the membrane. The available information suggests that domains 
3 and 4 appear to contain this point in segment 6, although some references also 
place it in segment 6 of Domain 1.
Among other tissues, sodium channels are located in excitable membranes such 
as the CNS membranes, peripheral nervous system, and the conduction system of 
the heart. During a nervous impulse, the cell goes through three different phases; it 
first depolarizes as the sodium channels open, then a refractory period follows until 
the cell finally repolarizes when the sodium channels become impermeable to Na+. 
The intracytoplasmic junction between Domain III and Domain IV (CI in Figure 2) 
is responsible for this inactivation according to the “ball and chain” model.
4. Mechanism of action of LAs
As mentioned before, LAs inhibit the electrical impulse by selectively interfering 
with the function of voltage-dependent sodium channels by preventing the trans-
port of Na+ through the ionic pore of sodium ionophores, from outside to inside of 
the cells. When an electrical impulse reaches the excitable cell, the sodium channel 
opens for a millisecond and about 7000 Na+ pass. A refractory period continues 
until the ionophores become impermeable to Na+, and the membrane repolar-
izes again and enters a phase of inactivation, which is due to the activation of the 
intracytoplasmic junction between Domain III and IV. Unlike the tetrodotoxin and 
saxitoxin that act outside the cell membrane, LAs are temporarily fixed to the alpha 
helices 6 of Domains 3 and 4, which alters the voltage sensor and closes the inactiva-
tion gate, which obstructs the sodium channel and results in blockage of the initial 
phase of the action potential [14, 21–23].
There are two ways by which LAs reach the internal gate of the sodium channel 
and reach their site of action;
a. It has been postulated that LAs in their neutral, lipophilic (hydrophobic, B) 
form easily enter the lipid cell membrane in free form and from there contribute 
to the closure of sodium channels by the expansion of the cell membrane. From 
this location, LAs also pass into the cellular interior where they ionize and 
transform into their charged form (hydrophilic, BH+), which reaches the site 
where they interact (segment 6 of Domains 3 and 4) in the internal gate of the 
sodium channel.
b. LAs in their cationic or hydrophilic form (BH+) enter the cell cytoplasm 
through the sodium channels when they are open and reach their site of action 
by closing the sodium channel [14, 20, 23, 24]. LAs have no effect on the resting 
phase or on the potential threshold, although they can prolong the refractory 
period and repolarization.
Figure 3 illustrates these two routes of arrival of LAs to their receptor site in 
segments 6 of Domains 3 and 4.
Another factor that determines the action of LAs is the impulse frequency, the 
basis of the modulated receptor hypothesis, which suggests that these drugs bind 
more closely to the receptor within the ionic gate of voltage-dependent sodium 
channels when these are in an open or inactive state, that is in the depolarization 
phase, that when they are in a resting state, at which time they are separated from 
them. LAs that bind and dissociate rapidly such as lidocaine are little affected 
by this phenomenon, which is not the case with molecules such as bupivacaine, 
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ropivacaine, or etidocaine that are benefitted when the stimulation frequency is 
high, since it does not give time to recover to their resting state. This phenomenon 
explains the greater toxicity of some LAs [24, 25].
The affinity of LAs for the sodium channel is what determines their pharmaco-
logical action and also their toxic effects. The most important clinical outcome of 
these events at the level of voltage-dependent sodium channels and their interaction 
with LAs molecules are two results: regional anesthesia-analgesia and/or deleterious 
toxic effects.
5. Chemical structure of LAs
LAs are divided into two groups according to their chemical structure: the amino 
esters (cocaine, procaine, chloroprocaine, and tetracaine) and the amino amides 
(lidocaine, bupivacaine, mepivacaine, ropivacaine, and prilocaine). The typical 
molecule of a LA consists of three components: a) an aromatic lipophilic ring, 
usually benzene, b) an amphipathic intermediate chain of about 6 to 9 Å, and c) 
a terminal tertiary amine, hydrophilic, which is a base proton acceptor (H+). The 
intermediate chain binds the basic amine with the aromatic ring and has an ester 
(CO)- or amide (CNH)-type bond. Each of these three parts of the LA formula 
contributes to different properties. The aromatic ring of the molecule improves 
the liposolubility of the compound that can be increased by aliphatic substitutions 
at certain sites (R). When the liposolubility of LAs is increased, its diffusion is 
increased through nerve structures (nerve sheaths and axonal membranes), which 
improves their anesthetic and toxic potency since a greater proportion of the drug 
enters the neural tissue and is fixed there with higher affinity. An example of this 
phenomenon is bupivacaine which has greater potency than lidocaine; the first 
Figure 3. 
Arrival pathways of LAs to the sodium channel. The hydrophobic pathway refers to the passage of LAs in their 
neutral (lipophilic) form that easily penetrate the cell membrane. Once in the cell membrane, the LA (B) 
expands it and by mechanical effect closes the sodium channel. This same neutral form of LA penetrates the 
cell, where it is protonized by incorporating an H+, (BH+ cationic form) that easily reaches the internal gate of 
the sodium channel and attaches to segment 6 of domains 3 and 4, activating the closure of the sodium channel. 
The hydrophilic pathway exemplified in the right portion of the scheme illustrates how a cationic LA (BH+) 
penetrates through and is fixed in the sodium channel.
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is prepared at 0.5% (5 mg/mL) and the second at 2% (20 mg/mL). The terminal 
amine may exist in tertiary form (3 junctions) that is liposoluble and facilitates 
cell membrane penetration, or as a quaternary form (4 junctions) that is positively 
charged and makes the molecule water soluble, which makes it difficult to pass 
through the lipid membranes [11, 25].
As stated before, the aromatic ring determines the degree of lipoafinity of the 
LA, and the terminal amine acts as an on-off switch, allowing the LA to exist as 
either lipoafin or water soluble. Both the tertiary and quaternary forms play a very 
important role in the sequence of events that lead to nerve conduction blockage. 
The tertiary hydrophilic amine, which is kept charged to the physiological pH 
and gives it its condition of weak bases with a positive charge, is the part that will 
be fixed to the receptor in the sodium channel of the cell membrane to exert the 
pharmacological effect. The presence of an ester or amide group in the intermediate 
chain provides the basis for their classification and also determines the metabolism 
of these substances. LAs with ester binding are readily hydrolyzed in the plasma by 
cholinesterase; instead, those with an amide junction are biotransformed by liver 
microsomes via the microsomal system. Figure 4 shows the elementary chemical 
structure of LAs.
If the size of the molecule of a LA is increased, its potency and duration of 
action increase but also its toxicity. There is a direct correlation between potency, 
duration of effect, lipophilic character, molecular size and toxicity. Chloroprocaine 
is the least toxic, followed by procaine, prilocaine, lidocaine, mepivacaine, etido-
caine, ropivacaine, bupivacaine, tetracaine and dibucaine, with cocaine being the 
most toxic LA.
Another aspect of capital importance is the stereoisomerism that some LAs 
have. It refers to the existence of molecules with the same structural and molecular 
formula, but with different spatial orientation around a particular atom, the chiral 
center. It is like a reflection in a mirror, like placing one hand next to the other; they 
are the same but cannot be superimposed, they are mirror images. LAs of the pipeco-
loxylidide family (mepivacaine, bupivacaine and ropivacaine), as well as etidocaine 
and prilocaine are chiral compounds, with an asymmetric carbon atom, which 
can exist in their enantiomeric form, such as mirror images. When the compound 
deflects the polarized light to the left it is an S-isomer (Sinus) or levo-isomer, if the 
light is rotated to the right it is an R-isomer (Rectus) or dextro-isomer. Although the S 
and R isomers have a similar pharmacological activity, the clinical importance of the 
isomerism is that the same drug can have different biological activity. For example, 
the S-enantiomers of amino-amide LAs produce greater vasoconstriction and have 
less systemic toxicity than D-isomer. The typical example of stereoisomerism is 
Figure 4. 
Typical structural formula of a local anesthetic.
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bupivacaine, which contains the dextro-isomer and levo-isomer. The mixture of 
both is known as racemic combination. Ropivacaine only has a L-isomer. Lidocaine 
and ametocaine are aquirales since they do not have stereoisomers. D-isomers have 
more affinity for sodium channels than L-isomers, this makes the former more toxic 
[26, 27]. Table 2 shows the chemical classification of LAs.
6. Physical properties, activity, and potency
LAs are small molecules 220–350 Daltons weight, weak bases, poorly soluble 
and unstable in water, and therefore, they must be combined with a strong acid to 
obtain a stable salt that is soluble in water at pH 4.7. The solubility in water is directly 
related to the degree of ionization and inversely related to the fat solubility. In 
solution, LAs exist in two forms: basic, nonionized (B) and acidic, cationic, ionized 
(BH+). The ratio between these two forms depends on the dissociation constant 
(Ka) of the conjugated acid and on the local concentration of H+ ions. At a specific 
pH for each LA, the concentration of B is equal to that of BH+. This pH is called pKa. 
The relationship can be expressed like this: pKa = pH-log (B) / (BH+). At a pH of 
7.40, the percentage of BH+ form will be higher the higher the pKa. Diffusion of a 
LA is passive. In order to act they must contact the axon and for this they must pass 
through the epineurium, perineurium and endoneurium of the peripheral nerve, as 
well as the myelin layer in the myelinated fibers (lipid-rich structures), and finally 
cross the cell membrane to be in contact with the receptor site on sodium channels. 
The fat-soluble basic form B diffuses easily through the perineural structures and 
the axonal membrane; once inside the cell it is protonized and it is this ionized form 
that occupies the aforementioned receptor site [23, 25].
The minimum inhibitory concentration (MIC) is necessary to block the con-
duction of a nerve impulse along a nerve fiber within a certain period. The MIC is 
different for each LA and allows to differentiate them according to their potency. 
Several factors can determine the Cm: the size of the fibers (higher MIC for the 
thicker ones), the pH (lower MIC at higher pH), calcium concentration (higher 
MIC at higher calcium concentration), and frequency of nerve stimulation (smaller 
MIC at higher frequency).
Due to the characteristics of the nerve fibers, LAs first block the unmyelinated 
fibers (C fibers, which correspond to the postganglionic neurons of the autonomic 
nervous system), those of nociceptive conduction (analgesia), propriocep-
tive, tactile sensitivity, and pressure (anesthesia), and finally, the motor fibers 
(motor block).
Amino ester Amino amide
Cocaine Dibucaine
Benzocaine Lidocaine
Procaine Mepivacaine
Tetracaine Prilocaine
2-cloroprocaine Bupivacaine
Etidocaine
Ropivacaine
Levobupivacaine
Table 2. 
Chemical classification of local anesthetics.
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The latency period of a nerve block is not linked to the potency of the LA, but 
seems to depend on its lipid solubility and pKa, that is, on the pH in which 50% 
of the molecules are in ionized form and 50% in nonionized form. The higher the 
pKa, the greater the latency time of a LA. On the other hand, the decrease in tissue 
pH can lengthen the latency time by limiting the formation of free base; instead, 
carbonation of a LA solution shortens its latency time. Alkalinization has also 
been shown to produce a better sensory and motor quality nerve block and may 
increase diffusion of block height. By alkalinizing LAs, their ionization increases 
and the percentage of fat solubility of the LA increases, facilitating its diffu-
sion through the lipid structures of the nerves, including the axonal membrane. 
The addition of 1 mL of sodium bicarbonate to 10 mL of lidocaine improves the 
onset of extradural or peripheral block for 3–5 min, also increasing its duration 
of action.
With the exception of cocaine and ropivacaine, LAs produce vasodilation. 
Adding a vasoconstrictor to LAs is an acceptable routine since two basic actions 
were demonstrated: increased duration of action and decreased absorption. It 
also increases the intensity of sensory and motor block in neuroaxial anesthesia. 
Epinephrine was one of the first drugs to be injected into the subarachnoid space: 
however, its use was not widespread as the initial results were disappointing. The 
local vasoconstriction produced by adrenaline favors the decrease in the absorp-
tion of LAs, which favor a longer interaction, in addition to decreasing blood 
concentrations levels and thus their potential for systemic toxicity. On the other 
hand, epinephrine has an effect on alpha2 receptors in the CNS, especially in the 
spinal cord, which could be another factor for the improvement it has in neuroaxial 
blocks. Higher concentrations of adrenaline 2: 000,000 (5 μg/mL) do not offer 
major advantages in terms of prolonging anesthesia or reducing plasma concentra-
tions. Never use solutions with adrenaline to infiltrate areas with terminal arterial 
circulation such as the fingers, the penis, the nasal tip, or other areas with critical 
arterial circulation, since it may promote ischemia and local necrosis.
Physico-chemical characteristics Relative potency in different 
blocks
Anesthetic pKa Ionized 
% at 
pH 7.4
Partition 
coefficient
% 
protein 
binding
Epidural Spinal Peripheral 
nerve
• Bupivacaine 8.1 83 3420 95 4 9.6 3.6
• Levobupivacaine 8.1 83 3420 97 4 9.6 3.6
• Etidocaine 7.7 66 7317 94 2 6.7 0.7
• Lidocaine 7.9 76 366 64 1 1 1
• Mepivacaine 7.6 61 130 77 1 1 2.6
• Prilocaine 7.9 76 129 55 1 ¿ 0.8
• Ropivacaine 8.1 83 775 94 4 4.8 3.6
• Chloroprocaine 8.7 95 810 — 0.5 — —
• Procaine 8.9 97 100 6 — — —
• Tetracaine 8.5 93 5822 94 — — —
*Modified from Salinas FV, Liu SL, Schlz AM. Analgesics. Ion channel ligands/sodium channels blockers/local 
anesthetics. Chapter 30. In: Evers AS, Maze M. Editors. Anesthetic pharmacology. Physiologic principles and clinical 
practice. Editorial Churchill-Livingstone. Philadelphia, USA. 2004 pag 507–537.
Table 3. 
Physical and chemical characteristics and relative potency of some local anesthetics *
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The phenomenon of tachyphylaxis or acute tolerance to LAs is characterized by 
a decreased effectiveness of a LA with repeated administration of the same dose. Its 
prevalence and mechanisms have not been well defined. This phenomenon occurs 
with different anesthetics, with different application techniques, and has been seen 
to develop more frequently when redosing is administered after the analgesic effect 
of the previous dose has ended [28, 29]. It has been mentioned that it could be due 
to a progressive acidification of the injection site that is established more rapidly 
with weak pKa LAs. A central mechanism through spinal cord sensitization that 
could be avoided by pretreatment with NMDA or nitric oxide antagonists has also 
been described [29–31].
The potency of LAs refers to the sensitivity of the neural tissue to the different 
LAs. This potency increases with increasing affinity for lipids. The binding capacity 
of LAs to the phospholipid membrane as a result of the physicochemical character-
istics and the interaction in vivo is directly related to their potency. Other factors 
affecting the potency of a LA include: hydrogen ion balance, fiber size, type, and 
myelination, vasodilator/vasoconstrictive properties (affects vascular absorption 
rate), frequency of nerve stimulation, tissue pH, and electrolyte concentrations 
(hypokalemia and hypercalcemia antagonize the block).
Table 3 shows some physical and chemical characteristics as well as the relative 
potency of some frequently used LAs.
7. Pharmacokinetics
The anesthetic and analgesic results of the injection of a LA in the vicinity of the 
neural tissue depend on the factors that have already been described. Plasma levels 
are affected by the injection site, the degree of absorption, its tissue distribution, its 
metabolism, and elimination, among other factors that have already been discussed.
7.1 Absorption
The quantity of LA that is absorbed from its application site and reaches the 
bloodstream is an important toxicity and elimination factor. LAs with poor absorp-
tion are safer. The absorption depends, on one hand, on the characteristics of the 
tissue; it increases in very vascularized territories and diminishes in fatty tissue. 
The plasma concentration depends on the total dose administered rather than the 
concentration, for most LAs there is a linear relationship between total dose and 
blood concentration [32]. On the other hand, the physicochemical characteristics 
also modulate the absorption of the drug, for example, the most lipophilic LAs 
and with greater affinity for proteins will be absorbed more slowly than those with 
less affinity for fatty tissue. Remember that the most lipophilic are also the most 
potent LAs. The decrease in absorption when adrenaline is added is more effective 
for LAs of short action and lower potency [33, 34]. With this, gradual absorption is 
achieved, the duration of action is prolonged and plasma levels are decreased as well 
as hemorrhage in the operative field.
7.2 Distribution
It depends on the physicochemical characteristics of each LA, its coefficient of 
solubility and plasma protein binding. A higher coefficient of solubility together 
with a lower degree of protein binding favors an easier distribution in peripheral 
tissues and a lower plasma concentration. LAs cross the blood-brain and placental 
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barriers by simple diffusion; this diffusion is greater when the ability to bind to 
plasma proteins is lower. Variable levels bind to plasma proteins in the bloodstream, 
particularly alpha-1- glycoprotein acid. This protein-binding property correlates 
with its affinity for sodium channels and predicts the duration of neural blockage. 
Bupivacaine has the highest percentage of protein binding and is therefore the LA 
with the longest duration of action.
7.3 Metabolism and elimination
LAs differ in their metabolism according to their chemical structure; those with 
ester-type binding (except cocaine) are rapidly hydrolyzed by plasma esterases, so 
the duration of their action increases with the deficit of this enzyme or the presence 
of atypical cholinesterase. Cocaine is hydrolyzed in the liver. The metabolites of the 
esters are eliminated by the kidney.
Amide LAs are metabolized in the liver. This is a slow process, which favors a 
longer half-life than esters and can accumulate when repeated doses or infusions are 
administered. Liver function interferes with the elimination of these drugs; extrac-
tion, perfusion and hepatic metabolism are definitive factors, as it is the degree of 
protein binding. The metabolites and the nonmetabolized drug are eliminated by 
urine and a small amount by feces. Elimination is favored by an acid urinary pH. 
Prilocaine is metabolized outside the liver.
The fact that amino ester-type LAs are rapidly metabolized favors that they 
remain in the blood for a short period of time, including placental blood and the 
fetus. Those of the amino-amide type pass more easily to the fetus, especially those 
with lower affinity to plasma proteins such as lidocaine, which can result in fetal 
toxicity. When the fetus has been compromised by any pathology and is acidotic, 
more ionization of the LA that has passed into its fetal circulation is favored. In this 
way the LA will remain longer in the fetus with the possibility of severe toxicity. 
In the newborn, this toxicity can be accentuated since there is no hepatocellular 
maturity.
8. Clinical aspects
LAs are one of the most commonly used drugs in clinical anesthesia; either by 
the neuroaxial route, in the vicinity of nerves and nerve plexuses, subcutaneous, 
transcutaneous, trans mucosal, intraarticular, and intravenously. The introduction 
of levoisomeric LAs, the evolution of regional anesthesia techniques with the rec-
ommendations of epidural test dose with a vasoactive marker, fractional peridural 
doses, low and intrathecal minidose, multiple injections with low volumes for nerve 
plexuses blocks, the use of nerve stimulator, guides with ultrasound and other 
imaging techniques, as well as the addition of adjuvant drugs such as opioids, alpha2 
agonists, NMDA receptor antagonists, among others have done regional anesthesia 
safer. Tables 4 and 5 categorize the most important formulas and characteristics of 
LAs most commonly used in anesthesiology.
8.1 Amino ester LAs
The precursor of this group is cocaine. They are characterized by being metabo-
lized by plasmatic esterases, short half-life and being related to allergic reactions. 
The most commonly used are procaine, chloroprocaine, and tetracaine. Benzocaine 
has no use in regional anesthesia.
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8.2 Amino amide LAs
They are the most used in regional anesthesia. Lidocaine is the typical anesthetic 
with which almost all new drugs in this group have been compared. Even when they 
have differences such as latency time, duration, and toxicity they have a mechanism 
of action common to all LAs. They can be divided into two large groups: those of 
short duration and those of long duration.
Slow long-release of LAs are recent advances that have improved the manage-
ment of postoperative pain. Nanostructured carriers, such as liposomes and 
polymers, facilitate the prolonged release of LAs. Exparel® was the first approved 
liposomal LA to combine racemic bupivacaine with liposomes. Polymersomes have 
advances over liposomes with complementary profiles, inspiring the emergence 
of hybrid carriers [35, 36]. Also, multilamellar vesicles with ropivacaine are being 
investigated to prolong its analgesic effect [37].
Formulae Important features
In addition to blocking the impulse of axonal conduction, it has the 
ability to inhibit neurotransmitter recapture in adrenergic neuronal 
endings, which means accumulation of norepinephrine in sympathetic 
synapses inducing vasoconstriction and cardiac stimulation. In the CNS, 
the accumulation of norepinephrine causes stimulation; however, some 
adrenergic neurotransmitters in the CNS are inhibited, in particular the 
dopamine recapture resulting in euphoria and abuse potential. Its clinical 
utility is limited to topical anesthesia, in solutions 4 and 10%. Due to its 
vasoconstrictor action, it has been used in anesthesia of the nasal mucosa to 
facilitate nasotracheal intubation.
It has been used at 0.5, 1, 2, 5, and 10% for infiltration, peripheral, and 
spinal blocks. Procaine is of special interest in dentistry in 2% solution 
with 1:50,000 adrenaline. The allergic capacity of para-aminobenzoic acid 
(PABA) limits its clinical utility. The maximum doses are 750 mg with 
adrenaline and 500 mg without vasoconstrictor. It has been used by the 
subarachnoid route in increasing concentrations to establish the differential 
diagnosis in some painful syndromes.
It is used in solutions 1, 2, and 3% for infiltration, peripheral blockages, 
and epidural anesthesia. Due to its brief time of action, it is very useful 
in peridural block in cesarean section. The neurotoxicity observed after 
intrathecal injection, attributed to the sodium bisulfite in the solution, has 
limited the wide use caused by its low systemic toxicity. The maximum 
recommended doses are 800 mg with adrenaline and 600 mg without it. 
There are studies that favor intrathecal injection of chloroprocaine without 
methylparaben.
Useful in topical anesthesia in the form of ointment, chewable tablets, and 
gel. It is poorly soluble and remains in the place of its application. It is not 
used in regional anesthesia.
It has pKa of 8.46, plasma protein binding of 75.6% and N-heptane / water 
partition coefficient of 4.1. Despite its high systemic toxicity, it has been 
used in subarachnoid anesthesia in hyperbaric solutions 1 and 2% due to its 
high efficacy. Its latency is not very long, and the duration of the anesthetic 
effect is 2 to 3 hours, because its plasma hydrolysis is quite slow. Its use has 
been replaced by levoisomeric anesthetics.
Table 4. 
Formulae and characteristics of amino ester local anesthetics.
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Formulae Most important features
It is the prototype in this group. After intravenous administration, the 
apparent volume of distribution is 92 L. Its alpha half-life is 8.3 min, 
its beta half-life is 108 min, and its plasma clearance 0.77 L/min. Its 
metabolism is hepatic, with an extraction coefficient of 0.7. The 
addition of adrenaline decreases its passage to the blood by 30%. It 
has a duration of action that varies from 2 to 3 hours depending on 
the site of administration and the addition of adrenaline. The toxic 
neurological manifestations of lidocaine are directly proportional 
to plasma levels. If these are low (0.5 to 4 mg / mL); lidocaine is 
anticonvulsant, at higher levels (8 mg/mL) it can cause seizures.
In the heart, lidocaine blocks sodium channels, decreasing 
contraction (V max), the amplitude and duration of the action 
potential, and increases the duration of the refractory period. 
These effects are only observed with elevated plasma levels. The 
action on the heart can be summarized in: dose automatism: 
below 5 mg/mL, onset of sinus bradycardia; conduction: no 
modification (atrioventricular or intraventricular) at usual doses; 
contractility: decrease, but only at doses that cause frank toxicity. 
At low plasma levels, lidocaine increases vascular tone; at higher 
levels vasodilation occurs. Direct intravascular injection does not 
produce obvious hemodynamic alterations as long as the dose 
is not greater than 3 mg/kg. From 4 to 8 mg/kg, cardiovascular 
depression occurs, which is dangerous if the dose is greater than 
8 mg/kg. If there is heart failure, the toxicity threshold decreases.
Its pharmacokinetic properties are similar to those of lidocaine, 
although it is less vasodilator. It is used in infiltration for peripheral 
nerve and in epidural anesthesia. The usual concentrations range 
between 0.5 and 2%. It is 40 times less toxic than lidocaine. An 
ideal use is intravenous regional anesthesia. A potential risk is the 
appearance of methemoglobinemia (total doses greater than 500 to 
600 mg), so its use in obstetrics is restricted or contraindicated.
First approved in Germany in 1976, in Canada in 1982 and in 
2000 by the FDA. It has a thiophene group, an ester group and 
also an amide group. It has been classified in the amide group 
by its intermediate chain and because it is metabolized in the 
liver. However, its ester portion allows it to be degraded by 
plasma pseudocholinesterase. The mean maximum plasma drug 
concentration is about 400 μg/L for articaine with epinephrine 
1:200,000 and 580 μg/L without epinephrine. The elimination half-
time is approximately 20 min. The rapid breakdown to the inactive 
metabolite articainic acid is related to a very low systemic toxicity 
and consequently to the possibility of repeated injections. It has 
been associated with paresis and long-lasting paraesthesia, which 
are more frequent than those produced by lidocaine. It is commonly 
used in dentistry.
Its molecular formula is C15H22N2O-HCL, soluble in water and 
very resistant to acid and alkaline hydrolysis. It is available in 
concentrations of 1%, 1.5% and 2%. The latency and duration of 
action are similar to those of prilocaine and its potency resembles 
lidocaine. Useful concentrations range between 0.5 and 2%. It 
diffuses well through tissues, which allows favorable blocking 
despite a less optimal needle placement. It produces an intense 
motor block. It is used to perform infiltration, peridural and spinal 
anesthesia (with a lower incidence of neurological alterations than 
lidocaine). Its use is not advised in obstetrics based on its prolonged 
metabolism in the fetus and in the newborn. It is recommended for 
peripheral nerve blocks in certain conditions: patients with cardiac 
risk or with drugs that potentiate toxicity. Adrenaline decreases 
the absorption of mepivacaine but does not prolong its duration of 
action.
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8.3  There are 3 LAs: articaine, sameridine, and centbucridine, which due to 
their special physico-chemical characteristics deserve a brief description
8.3.1 Articaine
It is a short-acting LA with intermediate potency. It has been included in the 
amide group, but it contains an additional ester group that is quickly hydrolyzed 
by esterases, a chemical characteristic that accelerates its metabolism. The plasma 
protein binding rate of articaine and articainic acid is 70%. I.V. articaine 80 mg 
does not produce toxic effects in healthy individuals. It has been used neuraxially, 
ocularly, intravenously, and in regional blocks. It is suitable and safe for procedures 
requiring a short duration of action in which a fast onset of anesthesia is desired, 
Formulae Most important features
It is more fat-soluble and has a higher degree of affinity to plasma 
proteins than lidocaine, has a short latency and longer duration. 
Epidural route is used at 0.5 to 1%. It produces greater motor 
blockage than sensitive which makes it useful in abdominal surgery, 
its use in obstetric analgesia anesthesia is not advised. Its beta half-
life is 2.5 hours, and care should be taken in liver disorders because 
of the prolonged action.
It is a racemic mixture, long-acting drug that produces a differential 
sensory-motor block at low concentrations. It has a limited placental 
transfer, so it is widely used in obstetrics in concentrations of up to 
0.5%. Higher concentrations are not recommended in obstetrics. It is 
the LA with greater cardio and neuro toxicity and greater difficulty 
in resuscitation since it has a great affinity for voltage-dependent 
sodium channels. However, after lidocaine, it is the most used. It is 
widely used in pain clinic.
It is bupivacaine levoisomer. It has pharmacological properties 
similar to bupivacaine but less toxicity. Its toxicity depends on 
the route of administration and the dose, its pharmacokinetic 
is similar to bupivacaine and its plasma peak is 30 min after 
epidural administration, with an alpha-glycoprotein and albumin 
binding greater than 97% at concentrations of 0.1 at 1 ug/mL. 
It is metabolized in the liver and the kidney does not seem to 
intervene in its elimination. Produces differential blockade similar 
to bupivacaine, which depends on the dose and concentration, 
which will be less than 0.25% such as 0.0625 and 0.125% for 
epidural analgesia, and 0.5% to 0.75% for neuroaxial anesthesia and 
peripheral nerve blocks.
The first levoisomeric LA for clinical use. The plasma alpha 
glycoprotein binding is 95%, with a pKa of 8.1 and a partition 
coefficient of 141. Due to its low absorption, it has a longer 
elimination half-life and its pharmacokinetic has a linear 
proportional to the dose, with a volume of distribution of 47 
liters. Like bupivacaine, it has a greater effect on C fibers than A, 
which produces a sensory rather than motor block. The clinical 
experience is excellent in neuroaxial anesthesia and peripheral 
nerve blocks. It is of great value by epidural route (obstetrics), and 
in postoperative analgesia. It is characterized by a block of greater 
latency and long duration. Less analgesic potency than bupivacaine 
and levobupivacaine. It is less cardiotoxic and neurotoxic than 
bupivacaine with a better response to resuscitation. Usefull in pain 
clinic.
Table 5. 
Formulae and characteristics of local amino-amide type anesthetics.
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e.g., dental procedures and ambulatory spinal anesthesia. Its most frequent use is 
in dentistry, where it has demonstrated efficacy and safety. Complete anesthesia 
is achieved in 90% of cases, using articaine 4% 60–80 mg with epinephrine 1: 
200,000. It diffuses well through soft tissue and bone; concentration in the alveolus 
of a tooth in the upper jaw after extraction was about 100 times higher than that 
in systemic circulation. In comparative clinical trials, its effects were not gener-
ally significantly different from those of other short-acting LAs like lidocaine, 
prilocaine, and chloroprocaine. There is no conclusive evidence demonstrating 
above average neurotoxicity, although cases of frequent persistent paresthesia after 
articaine use have been described [38–41]. Saralaya et al. compared 4% articaine 
with 1:100,000 epinephrine versus 2% lidocaine with 1: 100,000 epinephrine in 
50 patients operated on the third molar. These authors found that the mean onset 
time for articaine and lidocaine was 3.16 ± 0.55 and 3.2 ± 0.48 min, respectively. 
Postoperative analgesia was longer in the articaine group and its duration of action 
was 289.04 ± 40 and 361.88 ± 40 min, respectively, compared to lidocaine, which 
is 144.2 ± 12 and 197.44 ± 25 min, respectively. These authors recommend articaine 
since it was more potent and with a longer duration of action with better postopera-
tive analgesia and could be considered as an alternative to lidocaine [42]. Even in the 
presence of pulpitis, articaine proved to be more effective than lidocaine in patients 
undergoing root canal treatment [43]. There is no information available on the use 
of articaine during lactation, so its use is not entirely recommended yet.
8.3.2 Sameridine
This drug has mixed characteristics: LA and μ-opioid partial agonist. It is 
structurally similar to meperidine. It is a compound that is still under investigation 
(N-ethyl-1-hexyl-N-methyl-4-phenyl-4-piperidine carboxyamide hydrochloride) 
mainly for spinal anesthesia. Liver hydroxylation is the primary metabolic pathway, 
and no local neurotoxicity has been found in animal studies. Its effect on respiration 
is directly related to plasma levels. In healthy volunteers [44] 25 mg vs. intrathe-
cal bupivacaine 15 mg has similar effects on resting ventilation. The ventilatory 
response to hypoxia and hypercarbia were found to be discreetly diminished in 
the group treated with sameridine. Intravenous doses of 0.73 mg/kg depress the 
ventilatory response to hypercarbia [45]. The clinical doses of 150 μg/kg have no 
significant effects on ventilation [46]. Intrathecal doses of 15–25 mg of sameridine 
are sufficient for inguinal and orthopedic surgery, respectively. Doses of 5–20 mg 
are comparable with 100 mg of intrathecal lidocaine. The advantage is that sameri-
dine produces residual analgesia and reduces the need for opioids in the first hours 
of the postoperative period [7, 8], so it could have a role in the management of 
postoperative pain.
8.3.3 Centbucridine
It is a nonester, nonamide LA, chemically known as 4-N-butylamino-1,2,3,4-
tetrahydroacridine hydrochloride. It is a quinolone derivative drug with LA effects 
synthesized in 1982 by Patnaik et al. [47–49]. It is 5 to 8 times more potent than 
lidocaine, while its LD50 is one fourth that of lidocaine. It has vasoconstrictor 
and antihistamine effects, rapid onset of action (1–3 min), duration of action is 
prolonged (2.5 hours), and no events of cardiotoxicity or neurotoxicity have been 
reported. Centbucridine has been investigated for infiltration, conjunctival sur-
face, in peripheral nerves, neuroaxial anesthesia, intravenous regional anesthesia; 
however, the majority of studies are in dental anesthesia [9, 50–52]. Most studies 
compare 0.5% centbucridine vs. 2% lidocaine, with similar anesthetic results, 
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although some have found longer anesthetic duration in patients who were treated 
with centbucridine [51, 53]. Centbucridine can be used with confidence in dental 
patients who cannot tolerate other LAs or when epinephrine is contraindicated.
8.4 Maximum dose of LAs
Another clinical aspect of capital interest is the maximum doses of each LA. 
The maximum recommended doses have been established arbitrarily by the phar-
maceutical industry [54] and vary according to the route of administration, the 
type of anesthetic, with or without vasoconstrictors, as well as the type of patient 
and surgery. Table 6 shows the maximum recommended doses for the most com-
monly used LAs, without these doses having been established by studies conducted 
specifically to determine the safest and most effective amounts of each. Note the 
variants, sometimes with important ranges; 200 mg of lidocaine is recommended in 
Europe, while in the United States this dose reaches 300 mg when epinephrine is not 
used. Notwithstanding these differences, it is advisable to stay below the maximum 
recommended dosage range to avoid undesirable toxic effects.
8.5 Adequate anesthetic technique
Regional anesthesia techniques are important not only in the expected results, 
but to reduce undesirable side effects of LAs. It is known that spinal anesthesia 
produces lower plasma concentrations of LAs, unlike interpleural injection that 
in theory results in higher concentrations, and therefore, could be the procedure 
that produces more toxic events. However, this situation is hypothetical, since toxic 
events occur more frequently in peripheral blockages and peridural injections. For 
different types of nerve blocks, the same total injected dose produces different 
blood concentrations for mepivacaine, lidocaine, prilocaine and etidocaine, with 
the intercostal block being the one that produces the highest blood absorption, 
followed by injections in the peridural space. Plexus nerve blocks and subcutaneous 
injection are those that have a lower degree of absorption of LAs.
8.6 Undesirable side effects
The anesthetic and analgesic effects of LAs and their toxicity originate in the 
same mechanism of action; its interaction in the sodium channels. The therapeutic 
efficacy and safety of LAs has been proven from the moment of their discovery and 
it was precisely the deleterious effects that prompted the search for safer agents.  
Maximum dose of lidocaine:
Without epinephrine
200 mg (in Europe), 300 mg (in USA)
With epinephrine (5 μg/mL)
500 mg in both regions
Maximum dose of PPX anesthetics:
Bupivacaine 150–175 mg
Levobupivacaine 150 mg
Ropivacaine 200–300 mg
Epinephrine 1: 200,000 reduces absorption of subcutaneous lidocaine by 50%, intercostal, epidural and 
brachial by 20–30%
Table 6. 
Maximum dose of LAs [54].
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In 1905 Braun mentioned the characteristics that a new LA should have: In addition 
to producing local anesthesia, any new drug in this abundant group should have the 
following properties: be less toxic than the standard available, it should not irritate or 
damage tissues, it must be soluble in water, and stable in solution, it must be able to mix 
with adrenaline, and must be rapidly absorbed into the cell membrane [55]. More than 
a century of these recommendations have passed, and we still use LAs that do not 
meet these characteristics. LAs are used with an acceptable safety margin, without 
being the ideal drug. The following paragraphs briefly describe the most interesting 
side effects due to their magnitude and frequency. For more information on toxicity 
read chapter 10 of this book.
8.6.1 Toxicity
The history of LAs toxicity began at the end of the 19th century, when clinicians 
of that time realized the deleterious effects of cocaine and began the search for 
better drugs. Albright’s editorial in 1979 [13] commented on six deaths due to car-
diovascular collapse after the administration of bupivacaine or etidocaine whipped 
up this investigation in such a rapid way that currently there are safer drugs. The 
most important systemic toxic reactions are on CNS and the cardiovascular system. 
The CNS is affected with lower plasma concentrations than those that cause cardio-
vascular toxicity and is manifested by alterations in cognition, seizures, and coma. 
Arrhythmias with or without cardiovascular collapse of difficult management and 
death occur in the cardiovascular system. The incidence of systemic toxicity has 
been reduced to 0.01%, with regional blockages being the most associated with 
these events (7.5/10,000). The current use of ultrasound-guided nerve blocks is 
likely to reduce these statistics. Toxic effects can be grouped into two large groups:
1. Toxic reactions to:
a. Systemic and local
b. Not related to the LAs
2. Allergic reactions
a. To the LA
b. To conservatives or antioxidants
Events due to toxicity still occur in expert hands and are more related to the type 
of block and the dose injected. Various factors have been described:
• Potency of the LA. The greater the fat solubility, the greater potency and more 
possibility of cardio and neuro toxicity.
• Isomerism. LAs that contain a dextroisomer are more toxic than levoisomers. 
The former have been shown to have a higher affinity for the effector site of 
sodium channels.
• Total administered dose (plasma concentration). Toxicity is related to plas-
matic concentration of AL, and this depends directly on the total administered 
dose. Epidural blocks and tumescent subcutaneous infiltrations use the highest 
doses of LAs and have been linked to toxic events.
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• Injection site. In general terms, the blood absorption of LAs varies according to 
the injection site, although it is modified by factors such as the type of anesthetic 
injected, the addition of vasoconstrictors, and the speed and frequency of injec-
tion. The interpleural route favors high absorptions due to the large injection 
surface and its vascularity. However, this route has not been more frequently 
related to systemic toxicity, perhaps due to the lung capacity to fix and eliminate 
the concentration of LA up to ~40%. Spinal administration does not produce 
systemic toxicity from small doses and decreased vascularity. Injections close 
to the brain (facial, nasal, oral, neck) have larger possibility of neurological 
systemic toxicity, either by direct intra-arterial injection or by retrograde flow 
that transports small doses of the LA directly to the brain tissue than induces 
seizures and coma [56].
• Patient’s health/ASA. Factors such as age, liver and kidney dysfunction, 
hypoxemia, acidosis, pregnancy, and pharmacological interactions (cyto-
chrome P450 inhibitors) modify the possibility of systemic toxicity.
In the ester group, cocaine remains the most toxic LA, and procaine and chloro-
procaine are the least potent and least toxic potency, not only in the ester group, but 
among all known LAs. In the amino-amide group racemic bupivacaine, etidocaine, 
and mepivacaine are more toxic than levobupivacaine and ropivacaine. Lidocaine 
and prilocaine are the least toxic in this group.
Cardiotoxicity. The toxic effects of LAs on the cardiovascular system are divided 
into two groups; the physiological changes that are generated with some regional 
anesthesia techniques and the effects that derive from the actions of these drugs 
on sodium, potassium, calcium channels, and beta myocardial receptors. These 
side effects on the cardiovascular system can be explained by the following four 
mechanisms:
1. Regional effect due to the blockage of sympathetic preganglionic fibers  
secondary to the neuroaxial injection of the LA.
2. A direct cardio depressant/arrhythmogenic effect due to sudden and elevated 
plasma concentrations of local anesthetic by intravascular injection or exag-
gerated absorption from the injection site.
3. Cardio depressant effect mediated through the CNS.
4. Systemic absorption of toxic dose can cause spinal depression and secondary 
circulatory collapse.
8.6.2 Neurotoxicity
The toxicity of LAs on the nervous system manifests itself in two areas; those 
that are triggered by high blood concentrations and are due to their action on 
sodium channels in the CNS, and those that are caused by the direct application of 
the anesthetic on or in the vicinity of neural structures, especially the injection of 
lidocaine in the subarachnoid space.
8.6.3 Myotoxicity
It is well known that continuous perineural injection and direct intramuscular 
injection of LAs have toxic effects on the striated muscle causing inflammatory 
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changes. These drugs act on external cell membranes and on the membranes of 
intracytoplasmic organelles, especially on the double mitochondrial membrane. 
Bupivacaine produces alterations in active intracellular oxidative metabolism by 
depolarizing the mitochondrial membrane and oxidation of the pyridine nucleo-
tide. This results in the opening of permeability transition pore (PTP), a type of 
channel located in intracellular membranes that plays an important role in various 
forms of cell death. Injury mechanisms involved early and late abnormalities to 
cytoplasmic calcium (Ca2+) homeostasis by the sarcoplasmic reticulum Ca2+ ATPase 
and cytochrome C release. All of these alterations were dependent on bupivacaine 
concentration and were only found in voluntary striated muscle mitochondria, 
while mitochondria from esophageal muscle were resistant to bupivacaine [57]. In 
rabbits, continuous axillary block with placebo vs. 0.25% bupivacaine, at 24 hours 
neutrophilic infiltration was found in the placebo group, while the group receiv-
ing bupivacaine had a large amount of eosinophils. One week later, lymphocytes, 
plasma cells, macrophages and fibroblasts were found with data of muscle regenera-
tion [58]. Zink et al. [59] compared bupivacaine vs. ropivacaine and demonstrated 
that the former induced necrosis and apoptosis of muscle fibers, while the latter 
produced less severe changes in porcine skeletal muscle. These same researchers 
[60] confirmed their initial results that bupivacaine 0.5% is more myotoxic than 
ropivacaine 0.75%, by inducing irreversible myonecrosis with calcium deposits, 
scar formation, and muscle regeneration. The incidence of myotoxicity in ophthal-
mic studies was 0.77%. Inflammatory changes within a few days after exposure 
marked the onset of myotoxicity, and muscle degeneration continued within the 
first week after exposure. Recovery time in human muscles ranged from 4 days 
to 1 year. None partial and complete recovery was observed in 61% and 38% of 
patients, respectively [61]. All LAs that have been studied have a similar myotoxic 
potential in terms of the tissue alterations produced, but they differ in the intensity 
of these lesions. Bupivacaine and chloroprocaine are the most toxic and procaine 
and tetracaine are the ones that produce minor alterations.
8.6.4 Allergies
True allergies to LAs are rare and generally occur more with ester-type, although 
allergies have been reported with amino-amide LAs, including new levoisomeric 
anesthetics [62]. These allergies have a highly variable frequency that ranges from 
1: 350 to 1:20,000 and fortunately most are trivial, although occasionally they are 
factors of significant morbidity and mortality. The incidence of true IgE-mediated 
LA allergy remains unclear and is presumed to be as low as 0.7–1%. On some 
occasions these reactions have been attributed to preservatives (methylparaben) 
or antioxidants (bisulfites) that are contained in some commercial presentations 
[63, 64]. When someone is reactive to a LA, they will be allergic to it for the rest 
of their life due to the response of mast cells that release chemical mediators that 
are responsible for the clinical responses in each patient. These mediators include 
histamine, leukotrienes, chemotactic substances, lysosomal enzymes, prostaglan-
dins, kinins, and platelet activating factors that facilitate capillary permeation with 
plasma leakage in the surrounding area. The manifestations of true allergy range 
from mild to severe and sometimes are deadly. The faster the clinical manifesta-
tions occur, the more severe the reaction. The most frequent expression is contact 
dermatitis, but they can also manifest as urticaria, rash, rhinitis, bronchial spasm, 
angioneurotic edema, tachycardia, and hypotension and lead to anaphylactic 
shock. Immunoglobulin E-mediated anaphylaxis can induce respiratory failure and 
cardiopulmonary collapse. The treatment of true allergies to LAs depends on their 
severity; mild or moderate reactions disappear spontaneously. In severe reactions it 
Topics in Local Anesthetics
22
is recommended to use steroids, H1 blockers, antihistamines, or epinephrine. When 
there is a probable or proven history of allergy to LAs, caution should be exercised: 
if allergy to an ester compound is found, it should be switched to an amino-amide 
anesthetic, preferably one without methyl paraben or metabisulfite. When the 
allergy is to an amino-amide anesthetic, it is advisable to change to another anes-
thetic from the same group.
8.6.5 Methemoglobinemia
Prilocaine is metabolized to O-toluidine which can cause methemoglobinemia 
in susceptible individuals, especially when more than 500 mg is used. In pregnant 
women, this problem is even more critical since fetal blood poorly reduces methe-
moglobin. Management is with 1–5 mg of methylene blue.
8.6.6 Rebound pain
When the analgesic effect of a peripheral nerve block performed with LAs, a 
state of hyperalgesia known as rebound pain may occur 12–24 hours postopera-
tively, with intensity disproportionate for the type of the performed surgery. It has 
been classified as a complication of peripheral nerve blocks, the etiology of which is 
unknown. Several factors have been considered, including neurotoxicity of LAs, its 
effects on nociceptors, direct neurotrauma, the possibility of hyperalgesia induced 
by systemic opioids before or during the block. Its frequency is unknown, although 
it seems to be increasing, especially in outpatient surgery where it has been reported 
in up to 40%. It is a relevant complication since it hinders the postoperative evolu-
tion, disturbing sleep, increasing the opioid requirement and delaying hospital 
discharge. Preventive analgesia before the blockage subsides, intra-articular or 
intravenous anti-inflammatory drugs, and the use of adjuvants added to nerve-
block or systemic solutions can reduce rebound pain [65–67].
9. Nonanesthetic uses of LAs
Some nonanesthetic (off-label) uses of LAs have been described. Although 
these investigations have not been precisely determined, this topic deserves a brief 
description.
9.1 Cough, laryngospasm, and asthma
Lidocaine has been used successfully to prevent or treat cough and laryngospasm 
induced during tracheal extubation, as well as in patients with asthma and chronic 
cough difficult to treat [68–70]. The meta-analysis of Yang et al. found that iv 
lidocaine decreases postoperative airway complications [71]. Nebulized lidocaine 
has been used with encouraging results in patients with asthma, chronic cough, 
and laryngospasm; doses ranging from 10 to 400 mg are a therapeutic alternative in 
asthma and cough that is difficult to manage [72]. Its mechanism of action has been 
related to the decrease in airway inflammation via downregulation of TLR2 [73].
9.2 Effects of LAs on cancer
Regional anesthesia is preferably used in oncological surgery since it does 
not interfere with the immune system, and the postoperative outcome of these 
patients is better. On the other hand, there is evidence that LAs could have direct 
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antineoplastic effects [74, 75]. Some malignancies have increased voltage-depen-
dent sodium channel activity. Blocking these channels with LAs may help inhibit 
tumor progression [76]. Zheng et al. found an anti-melanoma activity of ropiva-
caine and lidocaine but not bupivacaine, via targeting small GTPases [77].
9.3 Antibiotics
Besides pain insensitivity, it has been shown that the in vitro and in vivo use of 
LAs have bacteriostatic, bactericidal, fungistatic, and fungicidal properties against 
a wide spectrum of microorganisms, this action being attributed to the interrup-
tion of the membrane permeability of microbial cells, leading to leakage of cellular 
components and subsequent cell lysis. Different LAs showed varying degrees of 
antimicrobial capacity; bupivacaine and lidocaine, for example, inhibit growth to 
a significantly greater extent than ropivacaine. Higher concentrations, prolonged 
exposure, and higher temperature correlate with a proportional increase in inhibi-
tion of microbial growth. Reducing the incidence of endophthalmitis after intravit-
real injection, prophylaxis for surgical wound infections, preventing the incidence 
of catheter-associated infections, reducing oral biofilms in the oral mucosa, and 
preventing infection-causing bacteria nosocomial are some examples of antimicro-
bial application of lidocaine [2, 78–80].
10. Conclusions
The first LA anesthetic was derived from the plant Erythroxylum coca, and 
regional anesthesia began in 1884 when Karl Köller anesthetized the cornea of 
his patients for surgical purposes. Since then, a host of events, drugs, discoveries, 
and various anesthesia techniques have culminated in safer and more effective 
regional anesthesia. LAs have an impressive history of efficacy and safety in 
medical and dental practice, but still have deleterious effects that can—on rare 
occasions—cause the death of our patients. Knowing the basics of the substrates 
where LAs work makes it easier to understand the action mechanisms that these 
drugs have on voltage-dependent sodium channels. The sequence of events that 
occur from the choice of the patient, the preparation and injection of LAs to the 
production of regional anesthesia-analgesia and/or its toxic effects are complex. 
These physiological and pathophysiological events depend on features as varied as 
the structural and physico-chemical characteristics, total injected dose, injection 
site, adjuvant drugs, physical condition of the patient, among others. The safe 
practice of regional anesthesia definitely reduces catastrophes, but these disasters 
can appear at any time. LAs have an impressive history of efficacy and safety in 
medical and dental practice.
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